Molecular Health Insolvency Leads to Restructuring Under New Company Name Lucera GmbH

Molecular Health, a German biotechnology company, has filed for insolvency but is set to continue operations under a new structure and name.

Molecular Health GmbH, a Heidelberg-based biotech firm, officially filed for insolvency on June 1st, 2026. The development was confirmed through public notices issued by the Mannheim District Court. According to these documents, the court has ordered self-administration proceedings, allowing the company to continue managing its operations during the restructuring process. Attorney Marc Schmidt-Thieme has been appointed as trustee to oversee the proceedings.

Molecular Health operates at the intersection of biotechnology and information technology, focusing on developing software solutions for the medical sector. The company has been supported by major investors, including Dievini Holding, an investment firm founded by SAP co-founder Dietmar Hopp.

Despite the insolvency filing, parts of the company’s business will continue. Reports indicate that an investor consortium plans to acquire the core operations of Molecular Health. These activities will be transferred to a newly established company named Lucera GmbH.

Leadership continuity appears to be a key element of this transition. Friedrich von Bohlen, founder of Molecular Health, will take on the role of chief executive officer at Lucera. He will be joined by Stephan Brock, who will serve as chief technology officer. According to regional media, von Bohlen maintains close ties with Dietmar Hopp, highlighting ongoing connections between the company’s leadership and its primary investor network.

The restructuring of Molecular Health will also affect the workforce

Of the approximately 60 employees currently working at Molecular Health, around 25 are expected to retain their positions and move to Lucera GmbH. The future of the remaining employees has not yet been clarified.

The case unfolds against the backdrop of a growing biotechnology sector in Germany. Over the past decade, the industry has experienced significant expansion. Between 2012 and 2022, revenues in the sector increased by 56 percent, according to the Federal Ministry for Economic Affairs. By 2024, Germany was home to 785 biotechnology companies, with numbers continuing to rise.

Public awareness of the sector increased substantially during the COVID-19 pandemic, particularly due to companies such as BioNTech and CureVac. Molecular Health’s restructuring reflects both the opportunities and challenges within this rapidly developing industry.

__

(Featured image by Melinda Gimpel via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in t-online. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.